Positron Corp POSC

$1.70 +0.03 (1.49%)

Valuation

Market cap
55,436,000
Revenue TTM
$460,000
Net income TTM
$-10,600,000
PE ratio
0.00
Forward PE
—
Profit margin
-2,304.35%
Debt to equity
0.00

Trading

Volume
215
Avg volume
18,344
Day's range
$1.70 – $1.70
Shares out
33,096,000
Stochastic %K
72%
Beta
0.53
Analysts
Strong Buy
Price target
$0.04

Price

Company profile

Positron Corporation, a medical technology company, co-develops, manufactures, and sells positron emission tomography and PET-computed tomography imaging systems in the United States. The company offers Attrius PET and NeuSight PET-CT 64-slice used in non-invasive diagnosis and evaluation of coronary artery disease and supports various molecular imaging applications, including cardiology, oncology, and neurology. It...

Show more

Positron Corporation, a medical technology company, co-develops, manufactures, and sells positron emission tomography and PET-computed tomography imaging systems in the United States. The company offers Attrius PET and NeuSight PET-CT 64-slice used in non-invasive diagnosis and evaluation of coronary artery disease and supports various molecular imaging applications, including cardiology, oncology, and neurology. It also provides clinical and technical support services, such as physician interpretation training, nurse and technologist training, billing and prior-authorization assistance, physician over-read services, 24/7 clinical and technical support, priority response with after-hours service availability, equipment uptime guarantees and software upgrades, and remote system diagnostics and maintenance capabilities. The company sells its products through internal sales and marketing team. It serves healthcare providers, imaging centers, hospitals, and cardiology practices. The company was incorporated in 1983 and is headquartered in North Tonawanda, New York.

Industry
Medical Devices
Sector
Healthcare
Phone
727 287 2800
Website
https://www.positron.com
Address
3784 Commerce Court, Suite 100, North Tonawanda, United States

Latest news

No headlines yet.